Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Monitoring secrets from North America’s largest healthcare services company
Learn about the cutting edge solutions McKesson implemented to optimise processes and deliver...
Minimise product contamination with elemental impurity testing
Learn about elemental impurity testing and how the recent innovation of microwave closed vessel...
Gene expression and miRNA data analysis
Automated analytical pipelines that are modular and flexible, combined with the use of...
